In this issue:
- PET-guided BrECADD vs. eBEACOPP in advanced-stage, classical Hodgkin lymphoma
- Vitamin D supplementation in early-stage CLL
- Obinutuzumab vs. rituximab for transplant-eligible mantle-cell lymphoma
- Stopping TKIs in CML
- Acalabrutinib-venetoclax obinutuzumab in relapsed/ refractory CLL
- Blinatumomab for MRD negative B-ALL
- MRD as an intermediate clinical endpoint in MM
- Predicting poor response and early relapse after BCMA directed therapy for MM
- Daratumumab in transplant eligible, newly diagnosed MM
- Belantamab mafodotin pomalidomide dexamethasone for MM
Please login below to download this issue (PDF)